Miragen Therapeutics, Inc. (MGEN): Kyle Lefkoff , director of Miragen Therapeutics, Inc. sold 5,902 shares on Feb 22, 2017. The Insider selling transaction was reported by the company on Feb 24, 2017 to the Securities and Exchange Commission. The shares were sold at $14.00 per share for a total value of $83,451.71 , the company said in a SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Miragen Therapeutics, Inc. is Initiated by Wedbush to Outperform and the brokerage firm has set the Price Target at $19. The Rating was issued on Feb 21, 2017.